EMA Accepts for Review the Marketing Authorization Application for Tisotumab Vedotin in Cervical Cancer

On February 2, Danish biotech company Genmab and Pfizer announced that the European Medicines Agency (EMA) has approved the review of the Marketing Authorization Application (MAA) for the antibody-drug conjugate (ADC) Tisotumab Vedotin. If approved, Tisotumab Vedotin will become the first ADC to receive EU marketing authorization for the treatment of cervical cancer patients.